Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his training in Internal Medicine and Hematology and Oncology at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School, an Institute Physician at the Dana-Farber Cancer Institute, and the Clinical Director of the Bing Center for Waldenström Macroglobulinemia. Dr. Castillo is the principal investigator in innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a Scientific Advisory Committee member at the International Waldenström Macroglobulinemia Foundation and a Scientific Committee member of the International Workshop for Waldenström Macroglobulinemia. He has authored over 350 peer-reviewed articles and has published his research in high-impact journals, including the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Blood. Dr. Castillo has been awarded the Innovation Award by the Dana-Farber Cancer Institute and the Robert A. Kyle Award by the International Workshop for Waldenström Macroglobulinemia. He is the Founder and Director of the WM-NET, a consortium composed of academic researchers in the United States focused on designing and executing clinical research in patients with Waldenström Macroglobulinemia.